Deficient Reporting and Interpretation of Non-Inferiority Randomized Clinical Trials in HIV Patients: A Systematic Review
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Non-inferiority (NI) randomized clinical trials (RCTs) commonly evaluate efficacy of new antiretroviral (ARV) drugs in human immunodeficiency virus (HIV) patients. Their reporting and interpretation have not been systematically evaluated. We evaluated the reporting of NI RCTs in HIV patients according to the CONSORT statement and assessed the degree of misinterpretation of RCTs when NI was inconclusive or not established. DESIGN: Systematic review. METHODS: PubMed, Web of Science, and Scopus were reviewed until December 2011. Selection and extraction was performed independently by three reviewers. RESULTS: Of the 42 RCTs (n = 21,919; range 41-3,316) selected, 23 were in ARV-naïve and 19 in ARV-experienced patients. Twenty-seven (64%) RCTs provided information about prior RCTs of the active comparator, and 37 (88%) used 2-sided CIs. Two thirds of trials used a NI margin between 10 and 12%, although only 12 explained the method to determine it. Blinding was used in 9 studies only. The main conclusion was based on both intention-to-treat (ITT) and per protocol (PP) analyses in 5 trials, on PP analysis only in 4 studies, and on ITT only in 31 studies. Eleven of 16 studies with NI inconclusive or not established highlighted NI or equivalence, and distracted readers with positive secondary results. CONCLUSIONS: There is poor reporting and interpretation of NI RCTs performed in HIV patients. Maximizing the reporting of the method of NI margin determination, use of blinding and both ITT and PP analyses, and interpreting negative NI according to actual primary findings will improve the understanding of results and their translation into clinical practice.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One study in the field of HIV assessed the interpretation of noninferiority trial results and showed spin in two-thirds of the studies with inconclusive results (55).”
From Misrepresentation and distortion of research in biomedical literature (2018) · cites this paper as [55]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Piaggio, G., Elbourne, D. R., Pocock, S. J., Evans, S. J. W., Altman, D. G., & CONSORT Group, F. T. (2012) · JAMA · doi:10.1001/jama.2012.87802 · Cited by 2,428 · cited 4×
“The extended Consolidated Standards of Reporting Trials (CONSORT) statement of 2006 [3] has updated recommendations to guide the conduct and reporting of NI trials.”
BackgroundMethodResultInfluentialGallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341 · cited 4×
“Gallant/2004/ Gilead 903 [11] Pharmaceutical company South America, Europe, USA 48 weeks TDF 300/plac qd +3TC 150 bid+EFV600 qd (n = 299) d4T40/plac bid +3TC150 bid+ EFV600 qd (n = 301) Proportion of patients with HIV RNA levels ,400 copies/ml at week 48.”
BackgroundMethodInfluentialReporting of Noninferiority and Equivalence Randomized Trials: An Extension of the CONSORT Statement
Piaggio, G., Elbourne, D. R., Altman, D. G., Pocock, S. J., Evans, S. J. W., & CONSORT Group, F. T. (2006) · JAMA · doi:10.1001/jama.295.10.1152 · Cited by 1,153 · cited 4×
“The extended Consolidated Standards of Reporting Trials (CONSORT) statement of 2006 [3] has updated recommendations to guide the conduct and reporting of NI trials.”
BackgroundMethodResultInfluentialPlint, A. C., Moher, D., Morrison, A., Schulz, K., Altman, D. G., Hill, C., & Gaboury, I. (2006) · Medical Journal of Australia · doi:10.5694/j.1326-5377.2006.tb00557.x · Cited by 872
Boutron, I. (2010) · JAMA · doi:10.1001/jama.2010.651 · Cited by 842 · cited 3×
“Boutron et al identified the nature and frequency of spin in superiority RCTs with statistically non-significant results for primary outcomes [8].”
BackgroundMethodResultInfluentialLennox, J. L., DeJesus, E., Lazzarin, A., Pollard, R. B., Madruga, J. V. R., Berger, D. S., Zhao, J., Xu, X., Williams-Diaz, A., Rodgers, A. J., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60918-1 · Cited by 625 · cited 1×
“Lennox/2009/ STARTMRK [23] Pharmaceutical company 14 countries 48 weeks RAL based combination regimen (400 bid)+ TDF/FTC (n = 281) EFV based combination regimen (600 qd)+ TDF/FTC (n = 282) Achievement of ,50 vRNA copies/ml at week 48.”
MethodMolina, J.-M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., Moyle, G., Mancini, M., Percival, L., Yang, R., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61081-8 · Cited by 486 · cited 1×
“Molina/2008/ CASTLE [19] Pharmaceutical company 29 countries 48 weeks ATV-RTV (300/ 100 qd)+TDF-FTC (300/200 qd) (n = 440) LPV-RTV(400/ 100 bid)+TDFFTC(300/200 qd) (n = 443) Proportion of patients with HIV RNA levels of ,50 copies/ml at 48 weeks.”
Kjaergard, L., & Als-Nielsen, B. (2002) · BMJ · doi:10.1136/bmj.325.7358.249 · Cited by 433 · cited 1×
“Secondarily, we stratified studies by a) year published: before 2007 vs since 2007; studies have shown improvement in reporting standards in RCTs post-CONSORT [9] and b) type of sponsor: government vs pharmaceutical companies; studies have shown that industry sponsored trials tend to draw pro industry conclusions (spo…”
MethodMolina, J.-M., Cahn, P., Grinsztejn, B., Lazzarin, A., Mills, A., Saag, M., Supparatpinyo, K., Walmsley, S., Crauwels, H., Rimsky, L. T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60936-7 · Cited by 405 · cited 2×
“In 2 studies, NI margin was selected based on investigators assumptions [12,24]; 4 studies based on other publications or reviews [11,14,35,46]; 2 studies based on guidelines [28,32]; 2 studies, calculated based on previous trial results [20,31]; one study based on investigators assumption and other publications and r…”
BackgroundMethodOrtiz, R., DeJesus, E., Khanlou, H., Voronin, E., van Lunzen, J., Andrade-Villanueva, J., Fourie, J., De Meyer, S., De Pauw, M., Lefebvre, E., et al. (2008) · AIDS · doi:10.1097/qad.0b013e32830285fb · Cited by 387
Cohen, C. J., Andrade-Villanueva, J., Clotet, B., Fourie, J., Johnson, M. A., Ruxrungtham, K., Wu, H., Zorrilla, C., Crauwels, H., Rimsky, L. T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60983-5 · Cited by 374 · cited 2×
“Cohen/2011/ THRIVE [28] Pharmaceutical company 21 countries 48 weeks RPV25 qd+N(t)RTIs (n = 340) EFV600 qd+N(t)RTIs (n = 340) Percentage of all patients who received at least one dose of RPV or EFV who had a confirmed virological response (viral load ,50 copies/ml) at 48 weeks.”
BackgroundMethodEron, J., Yeni, P., Gathe, J., Estrada, V., DeJesus, E., Staszewski, S., Lackey, P., Katlama, C., Young, B., Yau, L., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69155-1 · Cited by 344 · cited 1×
“Eron/2006/KLEAN [16] Pharmaceutical company USA, Europe, Canada 48 weeks FPV-RTV (700/ 100 bid)+ABC-3TC (600/300 qd) (n = 434) LPV-RTV(400/ 100 bid)+ABC-3TC (600/300 bid) (n = 444) Proportion of patients with HIV-1 RNA concentration ,400 copies/ml at 48 weeks and the proportion who permanently discontinued randomized…”
BackgroundMadruga, J. V., Berger, D., McMurchie, M., Suter, F., Banhegyi, D., Ruxrungtham, K., Norris, D., Lefebvre, E., de Béthune, M.-P., Tomaka, F., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61049-6 · Cited by 336
Eron, J. J., Young, B., Cooper, D. A., Youle, M., DeJesus, E., Andrade-Villanueva, J., Workman, C., Zajdenverg, R., Fätkenheuer, G., Berger, D. S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)62041-9 · Cited by 317 · cited 4×
“Our study highlights that reporting of the methodology of NI HIV trials is still deficient in comparison to previous evaluations [2,51].”
BackgroundMethodResultInfluential(2010) · The Lancet · doi:10.1016/s0140-6736(09)62067-5 · Cited by 286 · cited 5×
“Mugyenyi/2010/ DART [24] Government; Pharmaceutical company Uganda, Zimbabwe 4.”
InfluentialGood Enough: A Primer on the Analysis and Interpretation of Noninferiority Trials
Kaul, S., & Diamond, G. A. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-1-200607040-00011 · Cited by 272 · cited 2×
“There is also the case that both CIs can reach different conclusions, but this is an uncommon situation [55].”
BackgroundMethodQuality of Reporting of Noninferiority and Equivalence Randomized Trials
Le Henanff, A., Giraudeau, B., Baron, G., & Ravaud, P. (2006) · JAMA · doi:10.1001/jama.295.10.1147 · Cited by 263 · cited 2×
“The clinical and statistical reasoning behind the selection of the appropriate NI margin is essential to be appropriately described in the manuscript [2,5,6].”
BackgroundMolina, J.-M., Andrade-Villanueva, J., Echevarria, J., Chetchotisakd, P., Corral, J., David, N., Moyle, G., Mancini, M., Percival, L., Yang, R., et al. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181c990bf · Cited by 254 · cited 2×
“Molina/2010/ CASTLE [25] Pharmaceutical company 29 countries 96 weeks ATV-RTV(300/ 100 qd)+TDFFTC(300/200 qd) (n = 440) LPV-RTV (400/ 100 bid)+TDFFTC(300/200 qd) (n = 443) Proportion of patients with HIV RNA ,50 copies/ml at week 48.”
BackgroundSanne, I., Orrell, C., Fox, M. P., Conradie, F., Ive, P., Zeinecker, J., Cornell, M., Heiberg, C., Ingram, C., Panchia, R., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60894-x · Cited by 248 · cited 2×
“In one ARVnaı̈ve [24] study and one ARV-experienced [48] study upper 95% CI limit of the Hazard ratio was the NI margin.”
BackgroundPozniak, A. L., Gallant, J. E., DeJesus, E., Arribas, J. R., Gazzard, B., Campo, R. E., Chen, S.-S., McColl, D., Enejosa, J., Toole, J. J., et al. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000245886.51262.67 · Cited by 231 · cited 2×
“Pozniak/2006/ Study 934 [18] Unclear France, Germany, Italy, Spain, UK, USA 48 weeks EFV600+ TDF300+ FTC200 qd (n = 258) EFV600 qd+ZDV300/ 3TC150 bid (n = 259) Proportion of patients with HIV RNA levels ,400 copies/ml through week 48 according to the FDA algorithm for the TLOVR.”
MethodReporting in randomized clinical trials improved after adoption of the CONSORT statement
Kane, R. L., Wang, J., & Garrard, J. (2007) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.06.016 · Cited by 227 · cited 1×
“Secondarily, we stratified studies by a) year published: before 2007 vs since 2007; studies have shown improvement in reporting standards in RCTs post-CONSORT [9] and b) type of sponsor: government vs pharmaceutical companies; studies have shown that industry sponsored trials tend to draw pro industry conclusions (spo…”
MethodDeJesus, E., Herrera, G., Teofilo, E., Gerstoft, J., Buendia, C. B., Brand, J. D., Brothers, C. H., Hernandez, J., Castillo, S. A., Bonny, T., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/424009 · Cited by 226 · cited 2×
“DeJesus/2004/ CNA30024 [12] Pharmaceutical company USA, Europe, South America, Central America, Puerto Rico 48 weeks ABC300/plac bid +3TC 150 bid+EFV200 qd (n = 324) ZDV300/plac bid +3TC 150 bid+ EFV200 qd (n = 325) Proportion of subjects with plasma HIV-1 RNA levels #50 copies/ml at week 48 adjusted for randomization…”
MethodGathe, J. C., Ive, P., Wood, R., Schürmann, D., Bellos, N. C., DeJesus, E., Gladysz, A., Garris, C., & Yeo, J. (2004) · AIDS · doi:10.1097/01.aids.0000131332.30548.92 · Cited by 197
Martinez, E., Larrousse, M., Llibre, J. M., Gutierrez, F., Saumoy, M., Antela, A., Knobel, H., Murillas, J., Berenguer, J., Pich, J., et al. (2010) · AIDS · doi:10.1097/qad.0b013e32833a608a · Cited by 193 · cited 1×
“Martinez/2010/ SPIRAL [43] Government; Pharmaceutical company Spain 48 weeks Switch to RALbased therapy from RTV-boosted PI (n = 139) RTV-boosted protease inhibitorbased therapy (n = 134) Proportion of patients who were free of treatment failure at 48 weeks.”
MethodEron, J. J., Rockstroh, J. K., Reynes, J., Andrade-Villanueva, J., Ramalho-Madruga, J. V., Bekker, L.-G., Young, B., Katlama, C., Gatell-Artigas, J. M., Arribas, J. R., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70196-7 · Cited by 192 · cited 2×
“Two trials though inconclusive are not reported so: one trial [33] is reported as inferior while it has discordant results with ITT and PP analysis, with superiority established by PP analysis and one trial [24] mentions ‘‘the upper (but not lower) CI was higher than the predefined margin of NI’’.”
BackgroundResultArribas, J. R., Horban, A., Gerstoft, J., Fätkenheuer, G., Nelson, M., Clumeck, N., Pulido, F., Hill, A., van Delft, Y., Stark, T., et al. (2010) · AIDS · doi:10.1097/qad.0b013e3283348944 · Cited by 186 · cited 1×
“Arribas/2010/ MONET [45] Pharmaceutical company 11 European countries, Russia, Israel 48 weeks DRV/RTV 800/100 qd (monotherapy arm) (n = 127) DVR/RTV 800/ 100 qd+two nucleoside analogues (triple therapy arm) (n = 129) Treatment failure defined as two consecutive HIV RNA levels .”
BackgroundKatlama, C., Valantin, M. A., Algarte-Genin, M., Duvivier, C., Lambert-Niclot, S., Girard, P. M., Molina, J. M., Hoen, B., Pakianather, S., Peytavin, G., et al. (2010) · AIDS · doi:10.1097/qad.0b013e32833dec20 · Cited by 166
Pulido, F., Arribas, J. R., Delgado, R. B., Cabrero, E., González‐García, J., Pérez-Elı́as, M. J., Arranz, A., Portilla, J., Pasquau, J., Iribarren, J. A., et al. (2008) · AIDS · doi:10.1097/qad.0b013e3282f4243b · Cited by 153 · cited 1×
“Pulido/2008/ NCT00114933 [39] Pharmaceutical company Spain 48 weeks LPV/RTV monotherapy as maintenance therapy (n = 103) LPV/RTV +2 NRTIs as maintenance therapy (n = 102) Proportion of patients without therapeutic failure at 48 weeks.”
MethodMoyle, G. J., DeJesus, E., Cahn, P. E., Castillo, S. A., Zhao, H. H., Gordon, D. N., Craig, C., & Scott, T. R. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000147521.34369.c9 · Cited by 117 · cited 2×
“In 2 studies, NI margin was selected based on investigators assumptions [12,24]; 4 studies based on other publications or reviews [11,14,35,46]; 2 studies based on guidelines [28,32]; 2 studies, calculated based on previous trial results [20,31]; one study based on investigators assumption and other publications and r…”
MethodJohnson, M. A., Gathe, J., Podzamczer, D., Molina, J., Naylor, C., Chiu, Y., King, M. S., Podsadecki, T. J., Hanna, G. J., & Brun, S. C. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000242449.67155.1a · Cited by 116 · cited 1×
“Johnson/2006/ M02–418 [17] Pharmaceutical company 7countries (North America, Asia, Europe, Australia) 48 weeks LPV800/RTV200 qd+TDF300 qd+FTC200 qd (n = 120) LPV400/RTV100 bid+TDF300 qd+FTC200 qd (n = 80) Proportion of subjects with plasma HIV-1 RNA #50 copies/ml at week 48.”
ARTEN investigators, Soriano, V., Arastéh, K., Migrone, H., Lutz, T., Opravil, M., Andrade-Villanueva, J. F., Antunes, F., Perri, G. D., Podzamczer, D., et al. (2010) · Antiviral Therapy · doi:10.3851/imp1745 · Cited by 108 · cited 1×
“Soriano/2011/ ARTEN [27] Pharmaceutical company Argentina, Germany, Italy, Mexico, Poland, Portugal, Romania, Spain, UK, Switzerland 48 weeks NVP200 bid+fixed dose TDF300/ FTC200 qd; NVP 400 qd+fixed dose TDF300/FTC200 qd (n = 376) ATV300+ RTV100 qd+fixed dose TDF300/FTC200 qd (n = 193) Confirmed plasma HIV RNA ,50 co…”
MethodLessons From and Cautions About Noninferiority and Equivalence Randomized Trials
Gøtzsche, P. C. (2006) · JAMA · doi:10.1001/jama.295.10.1172 · Cited by 106
Laurent, C., Kouanfack, C., Laborde-Balen, G., Aghokeng, A. F., Mbougua, J. B. T., Boyer, S., Carrieri, P., Mben, J.-M., Dontsop, M., Kazé, S., et al. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70168-2 · Cited by 94 · cited 2×
“Laurent/2011/ ESTHER (ANRS12110) [31] Government Cameroon 2 years clinical monitoring alone (n = 256) clinical and lab monitoring (n = 237) Mean increase in CD4 cell count from treatment initiation to month 24.”
BackgroundMethodWangge, G., Klungel, O. H., Roes, K. C. B., de Boer, A., Hoes, A. W., & Knol, M. J. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013550 · Cited by 90 · cited 4×
“The clinical and statistical reasoning behind the selection of the appropriate NI margin is essential to be appropriately described in the manuscript [2,5,6].”
BackgroundMethodInfluentialHIV-1 natural viral suppressors: control of viral replication in the absence of therapy
Sajadi, M. M., Heredia, A., Le, N. M., Constantine, N. T., & Redfield, R. (2007) · AIDS · doi:10.1097/qad.0b013e328013d9eb · Cited by 84 · cited 1×
“Marchou/2007/ ANRS 106 [38] Government France 96 weeks Fixed intermittent treatment: 8 weeks off therapy followed by 8 weeks on therapy (n = 200) Constant combination ART (n = 203) Cumulative proportion of patients throughout the study reaching a confirmed CD4 cell count of less than 300610(6) cells/L, defined as immu…”
MethodSierra-Madero, J. G., Villası́s-Keever, A., Méndez, P., Mosqueda-Gómez, J. L., Torres-Escobar, I., Gutiérrez-Escolano, F., Juárez-Kasusky, I., Magaña-Aquino, M., Ramos-Santos, C., Pérez-Saleme, L., et al. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181cae4a1 · Cited by 62 · cited 2×
“Sierra-Madero/ 2010/NCT00162643 [26] Government Mexico 48 weeks EFV 600 qd+ AZT/3TC 300/150 bid (n = 95) LPV/RTV 400/ 100 bid+AZT/3TC 300/150 bid (n = 94) Proportion of patients with HIV-1 RNA ,50 copies/ ml at week 48.”
BackgroundEron, J. J., Yetzer, E. S., Ruane, P. J., Becker, S., Sawyerr, G. A., Fisher, R. L., Tolson, J. M., & Shaefer, M. S. (2000) · AIDS · doi:10.1097/00002030-200004140-00006 · Cited by 62 · cited 2×
“Eron/2000 [34] Unclear USA, Puerto Rico 16 weeks Combivir (3TC150/ ZDV300) bid+currently prescribed PI (n = 110) 3TC150 bid+ ZDV200 tid+a FDA-approved PI (n = 113) Treatment failure defined as HIV-1 RNA $0.”
BackgroundCastro, N. D., Braun, J. M., Charreau, I., Pialoux, G., Cotte, L., Katlama, C., Raffi, F., Weiss, L., Meynard, J., Yazdanpanah, Y., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/605674 · Cited by 60 · cited 2×
“All but two studies [21,40] claiming additional benefit had analysis performed to support their claims.”
BackgroundMethodGathe, J., Andrade-Villanueva, J. F., Santiago, S., Horban, A., Nelson, M. R., Cahn, P. E., Bogner, J. R., Spencer, D. C., Podzamczer, D., Yong, C., et al. (2010) · Antiviral Therapy · doi:10.3851/imp1803 · Cited by 59 · cited 1×
“Gathe/2011/ NCT00561925 [30] Pharmaceutical company North America, Australia, Latin America, Africa, Europe 48 weeks NVP XR400 qd (plus placebo)+TDF300+ FTC200 qd (n = 505) NVP IR200 qd (plus placebo)+TDF300+ FTC200 qd (n = 506) Sustained virologic response through week 48 (viral load ,50 copies/ml).”
BackgroundClumeck, N., Rieger, A., Bánhegyi, D., Schmidt, W., Hill, A. D., van Delft, Y., Moecklinghoff, C., & Arribas, J. R. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr199 · Cited by 59
Rey, D., Hoen, B., Chavanet, P., Schmitt, M., Hoizey, G., Meyer, P., Peytavin, G., Spire, B., Allavena, C., Diemer, M., et al. (2008) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkn471 · Cited by 58 · cited 3×
“All but two studies [21,40] claiming additional benefit had analysis performed to support their claims.”
BackgroundA randomized study of emtricitabine and lamivudine in stably suppressed patients with HIV
Benson, C. A., van der Horst, C., LaMarca, A., Haas, D. W., McDonald, C., Steinhart, C. R., Rublein, J., Quinn, J., Mondou, E., & Rousseau, F. S. (2004) · AIDS · doi:10.1097/00002030-200411190-00007 · Cited by 55 · cited 3×
“Benson/2004/FTC303/350 [36] Pharmaceutical company USA 48 weeks FTC200 qd+d4T or ZDV+a PI or NNRTI (n = 294) 3TC150 bid+d4T or ZDV+a PI or NNRTI (n = 146) Virologic failure at week 48 defined as two consecutive measurements of HIV-1 RNA .”
BackgroundMethodReynolds, S. J., Kityo, C. M., Hallahan, C. W., Kabuye, G., Atwine, D., Mbamanya, F., Ssali, F. N., Dewar, R. L., Daucher, M., Davey, R. T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010307 · Cited by 48 · cited 1×
“Reynolds/2010/ NCT00339456 [49] Government Uganda 72 weeks 5 days on, 2 days off ART/7 days on 7 days off ART (n = 57/32) continuous ART (n = 57) ART treatment failure determined by a plasma HIV RNA $10,000 copies on any one evaluation, a plasma HIV RNA level $1,000 copies on two consecutive measurements, a plasma HIV…”
MethodDesigning and interpreting HIV noninferiority trials in naive and experienced patients
Hill, A. M., & Sabin, C. A. (2008) · AIDS · doi:10.1097/qad.0b013e3282f5556d · Cited by 46 · cited 2×
“The recommended NI margin between 10 and 12% [53,54] was used in 17/23 (74%) ARV-naı̈ve and 11/19 (58%) ARV-experienced studies.”
BackgroundMethodMeynard, J., Bouteloup, V., Landman, R., Bonnard, P., Baillat, V., Cabie, A., Kolta, S., Izopet, J., Taburet, A. M., Mercié, P., et al. (2010) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq327 · Cited by 43 · cited 3×
“Meynard/2010/ KALESOLO [47] Government France 48 weeks LPV/RTV monotherapy (400/100 bid) (n = 87) Current combined antiretroviral treatment (cART) (n = 99) Proportion of patients with viral load ,50 copies at week 48 without modification of antiretroviral treatment during the study.”
BackgroundMethodVibhagool, A., Cahn, P. E., Schechter, M., Smaill, F., Soto-Ramírez, L. E., Carosi, G., Montroni, M., Pharo, C. E., Jordan, J. C., Thomas, N. E., et al. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004006 · Cited by 41 · cited 4×
“Four trials [11,14,34,36] were reported as equivalence trials when in fact they were NI trials.”
BackgroundMethodInfluentialZajdenverg, R., Podsadecki, T. J., Badal‐Faesen, S., Andrade-Villanueva, J. F., Gathe, J., Mingrone, H., Fredrick, L. M., Gaultier, I., Woodward, W. C., & Bernstein, B. M. (2010) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3181cbd21e · Cited by 34 · cited 2×
“Zajdenverg/2010/ M06–802 [46] Pharmaceutical company 17 countries in North America, South America, Europe, Africa, Australia 48 weeks LPV/RTV 800/200 qd +2 NRTIs.”
BackgroundMethodCampo, R. E., Cohen, C., Grimm, K., Shangguan, T., Maa, J., & Seekins, D. W. (2010) · International Journal of STD & AIDS · doi:10.1258/ijsa.2009.008487 · Cited by 27 · cited 1×
“Campo/2010/ NCT0013745382 [50] Pharmaceutical company USA 48 weeks (EFV-A): qd EFV(600), qd 3TC(300) and qd enteric-coated ddI (400 or 250 if weight ,60 kg) (n = 131) (EFV-B): qd EFV(600) plus continuation of current NRTIs (n = 131) Proportion of patients who maintained plasma HIV1 RNA levels ,50 copies/ml at week 48.”
MethodMethodological standards in non-inferiority AIDS trials: moving from adherence to compliance
Parienti, J., Verdon, R., & Massari, V. (2006) · BMC Medical Research Methodology · doi:10.1186/1471-2288-6-46 · Cited by 26
Kumar, P. N., Salvato, P., LaMarca, A., DeJesus, E., Patel, P., McClernon, D. R., Florance, A. M., & Shaefer, M. S. (2009) · AIDS Research and Therapy · doi:10.1186/1742-6405-6-3 · Cited by 19
Girard, P., Cabie, A., Michelet, C., Verdon, R., Katlama, C., Mercié, P., Morand‐Joubert, L., Pétour, P., Monchecourt, F., Chêne, G., et al. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp141 · Cited by 16 · cited 3×
“Girard/2009/COOL [42] Pharmaceutical company France 48 weeks qd maintenance regimen of a twodrug combination TDF300 and EFV600 (n = 71) Conventional qd three drug combination TDF300, 3TC300 and EFV600 (n = 72) Proportion of patients with plasma HIV-1 RNA ,50 copies/ml at week 48 in the absence of treatment modificatio…”
BackgroundMethodPorter, B. O., Anthony, K. B., Shen, J., Hahn, B. K., Keh, C. E., Maldarelli, F. M., Blackwelder, W. C., Lane, H. C., Kovacs, J. A., Davey, R. T., et al. (2008) · AIDS · doi:10.1097/qad.0b013e32831cc114 · Cited by 13 · cited 3×
“One study [41] was inferior and was rightly acknowledged so by the authors.”
BackgroundMethodStatistical Methods in Recent HIV Noninferiority Trials: Reanalysis of 11 Trials
Flandre, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022871 · Cited by 11 · cited 2×
“In a recent study, statistical methods of 11 HIV NI trials published in 2010 were analyzed [1].”
BackgroundMethodNadler, J. P., Gathe, J., Pollard, R. B., Richmond, G. J., Liao, Q., Griffith, S. K., Lancaster, C. T., Hernández, J. E., Pappa, K. A., & the ESS40011 (STARR) Study Team (2003) · BMC Infectious Diseases · doi:10.1186/1471-2334-3-10 · Cited by 11
Firnhaber, C. S., Azzoni, L., Foulkes, A. S., Gross, R., Yin, X., Amsterdam, D. V., Schulze, D., Glencross, D. K., Stevens, W. S., HUNT, G. M., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021450 · Cited by 9 · cited 1×
“Firnhaber/2011/ NCT00100646 [29] Government South Africa 72 weeks sequential 2,4 and 8 week ART interruptions (n = 27) continuous ART (n = 26) Proportion of CD4+ T cell count measurements .”
Background
Cited by
‘Spin’ in published biomedical literature: A methodological systematic review
Chiu, K., Grundy, Q., & Bero, L. (2017) · PLOS Biology · doi:10.1371/journal.pbio.2002173 · Cited by 317
Misrepresentation and distortion of research in biomedical literature
Boutron, I., & Ravaud, P. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1710755115 · Cited by 273
“One study in the field of HIV assessed the interpretation of noninferiority trial results and showed spin in two-thirds of the studies with inconclusive results (55).”
Defining the noninferiority margin and analysing noninferiority: An overview
Althunian, T. A., de Boer, A., Groenwold, R. H. H., & Klungel, O. H. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13280 · Cited by 215
Lazarus, C., Haneef, R., Ravaud, P., & Boutron, I. (2015) · BMC Medical Research Methodology · doi:10.1186/s12874-015-0079-x · Cited by 137
Althunian, T. A., de Boer, A., Klungel, O. H., Insani, W. N., & Groenwold, R. H. H. (2017) · Trials · doi:10.1186/s13063-017-1859-x · Cited by 94
“This is in line with the range of margins that were defined by expert opinions in previous reviews (25 to 75%) [9, 11, 22, 23].”
Result
Metadata
- Authors
- Hernandez, A. V., Pasupuleti, V., Deshpande, A., Thota, P., Collins, J. A., & Vidal, J. E.
- Affiliations
- Case Western Reserve University (US)
- Cleveland Clinic (US)
- EsSALUD (PE)
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-03
- Volume
- 8
- Issue
- 5
- Pages
- e63272
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3643946
- OpenAlex
- W2047788079
- Cited by
- 29
- References
- 55
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 2 · 2022: 2 · 2021: 2 · 2020: 3 · 2019: 3 · 2018: 2 · 2017: 6 · 2016: 1 · 2015: 4
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by-nc-nd)
- Funders
- Cleveland Clinic
- Topics
- Physical Sciences › Mathematics › Statistics and Probability › Statistical Methods in Clinical Trials
- Social Sciences › Decision Sciences › Statistics, Probability and Uncertainty › Meta-analysis and systematic reviews
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Keywords
- HIV, antiretroviral drugs, trial reporting quality, CONSORT, non-inferiority margin, blinding, intention-to-treat analysis, per-protocol analysis, secondary outcomes
- MeSH terms
- Data Interpretation, Statistical, Drug Administration Schedule, Humans, Research Design, HIV Infections, Randomized Controlled Trials as Topic, Databases, Bibliographic, Treatment Outcome, Anti-HIV Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
